Literature DB >> 25544036

N-terminal pro-brain natriuretic peptide in acute Kawasaki disease correlates with coronary artery involvement.

Philippe M Adjagba1, Laurent Desjardins1, Anne Fournier1, Linda Spigelblatt2, Martine Montigny3, Nagib Dahdah1.   

Abstract

BACKGROUND: We have lately documented the importance of N-terminal pro-brain natriuretic peptide in aiding the diagnosis of Kawasaki disease.
OBJECTIVES: We sought to investigate the potential value of N-terminal pro-brain natriuretic peptide pertaining to the prediction of coronary artery dilatation (Z-score>2.5) and/or of resistance to intravenous immunoglobulin therapy. We hypothesised that increased serum N-terminal pro-brain natriuretic peptide level correlates with increased coronary artery dilatation and/or resistance to intravenous immunoglobulin.
METHODS: We carried out a prospective study involving newly diagnosed patients treated with 2 g/kg intravenous immunoglobulin within 5-10 days of onset of fever. Echocardiography was performed in all patients at onset, then weekly for 3 weeks, then at month 2, and month 3. Coronary arteries were measured at each visit, and coronary artery Z-score was calculated. All the patients had N-terminal pro-brain natriuretic peptide serum level measured at onset, and the Z-score calculated.
RESULTS: There were 109 patients enrolled at 6.58±2.82 days of fever, age 3.79±2.92 years. High N-terminal pro-brain natriuretic peptide level was associated with coronary artery dilatation at onset in 22.2 versus 5.6% for normal N-terminal pro-brain natriuretic peptide levels (odds ratio 4.8 [95% confidence interval 1.05-22.4]; p=0.031). This was predictive of cumulative coronary artery dilatation for the first 3 months (p=0.04-0.02), but not during convalescence at 2-3 months (odds ratio 1.28 [95% confidence interval 0.23-7.3]; p=non-significant). Elevated N-terminal pro-brain natriuretic peptide levels did not predict intravenous immunoglobulin resistance, 15.3 versus 13.5% (p=1).
CONCLUSION: Elevated N-terminal pro-brain natriuretic peptide level correlates with acute coronary artery dilatation in treated Kawasaki disease, but not with intravenous immunoglobulin resistance.

Entities:  

Keywords:  Kawasaki disease; N-terminal pro-brain natriuretic peptide; coronary artery involvement; prediction; predictive value

Mesh:

Substances:

Year:  2014        PMID: 25544036     DOI: 10.1017/S1047951114002431

Source DB:  PubMed          Journal:  Cardiol Young        ISSN: 1047-9511            Impact factor:   1.093


  5 in total

1.  Identification of novel locus associated with coronary artery aneurysms and validation of loci for susceptibility to Kawasaki disease.

Authors:  Clive Hoggart; Chisato Shimizu; Jane C Burns; Michael Levin; Rachel Galassini; Victoria J Wright; Hannah Shailes; Evan Bellos; Jethro A Herberg; Andrew J Pollard; Daniel O'Connor; Shing Wan Choi; Eleanor G Seaby; Stephanie Menikou; Martin Hibberd; Neneh Sallah; David Burgner; Paul Brogan; Harsita Patel; Jihoon Kim; Adriana H Tremoulet; Eeva Salo; Diana van Stijn; Taco Kuijpers
Journal:  Eur J Hum Genet       Date:  2021-03-26       Impact factor: 4.246

2.  Coronary Artery Dilatation in Viral Myocarditis Mimics Coronary Artery Findings in Kawasaki Disease.

Authors:  Soha Rached-D'Astous; Ibtissama Boukas; Anne Fournier; Marie-Josée Raboisson; Nagib Dahdah
Journal:  Pediatr Cardiol       Date:  2016-05-27       Impact factor: 1.838

Review 3.  A Decade of NT-proBNP in Acute Kawasaki Disease, from Physiological Response to Clinical Relevance.

Authors:  Audrey Dionne; Nagib Dahdah
Journal:  Children (Basel)       Date:  2018-10-12

4.  Is there an association between intravenous immunoglobulin resistance and coronary artery lesion in Kawasaki disease?-Current evidence based on a meta-analysis.

Authors:  Xiaolan Zheng; Jinhui Li; Peng Yue; Lei Liu; Jiawen Li; Kaiyu Zhou; Yimin Hua; Yifei Li
Journal:  PLoS One       Date:  2021-03-25       Impact factor: 3.240

Review 5.  Kawasaki Disease.

Authors:  Christian M Hedrich; Anja Schnabel; Toni Hospach
Journal:  Front Pediatr       Date:  2018-07-10       Impact factor: 3.418

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.